Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data

Volume: 133, Pages: 58 - 73
Published: Jan 1, 2019
Abstract
Mutation or epigenetic silencing of homologous recombination (HR) repair genes is characteristic of a growing proportion of triple-negative breast cancers (TNBCs) and high-grade serous ovarian carcinomas. Defects in HR lead to genome instability, allowing cells to acquire the multiple genetic alterations essential for cancer development. However, this deficiency can also be exploited by using DNA damaging agents or by targeting compensatory...
Paper Details
Title
Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data
Published Date
Jan 1, 2019
Volume
133
Pages
58 - 73
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.